AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Galactosemia

Recent research efforts aimed at curing Galactosemia.

Last updated
Also available in
Français — Galactosémie

Galactosemia

Overview

Galactosemia is a group of inherited disorders in which the body cannot properly process galactose, a sugar released when lactose in milk is digested. This report focuses on classic galactosemia, the severe form caused by very low or absent activity of galactose-1-phosphate uridylyltransferase (GALT), an enzyme encoded by GALT. Untreated newborns can become critically ill with feeding problems, liver injury, bleeding, cataracts, and E. coli sepsis. Classic Galactosemia and Clinical Variant Galactosemia

Newborn screening and immediate removal of lactose and high-galactose foods prevent most acute neonatal deaths. However, this is not a cure: despite early, lifelong dietary treatment, many people develop speech and learning difficulties, movement problems or tremor, and, in most affected females, premature ovarian insufficiency. Classic Galactosemia and Clinical Variant Galactosemia Current care also includes regular metabolic, developmental, speech-language, neurologic, bone-health, and reproductive follow-up. International clinical guideline

Scope of Recent Research (2020–present)

Research since 2020 has been active but remains concentrated in a small rare-disease community. The central questions are whether restoring GALT can safely correct the underlying defect, whether reducing harmful metabolites can prevent long-term brain and ovarian complications, and which biomarkers truly predict meaningful patient benefit. The field has produced strong animal proof-of-concept results for viral gene replacement and messenger RNA (mRNA) therapy, but no curative treatment has yet entered human clinical testing. Reshaping the treatment landscape

Major Breakthroughs and Emerging Therapies

Gene replacement. A notable preclinical advance used adeno-associated virus serotype 9 (AAV9), a commonly used gene-delivery vector, to supply a working human GALT gene to newborn GALT-null rats. Treated animals showed higher GALT activity, lower galactose, galactitol, and galactose-1-phosphate (Gal-1-P) in blood and tissues, and fewer cataracts. This is an important demonstration that early systemic gene replacement can correct biochemical disease in both liver and brain, although it was a short-term rat study rather than a human trial. AAV9 GALT gene replacement in rats

mRNA replacement. Lipid nanoparticles carrying laboratory-made human GALT mRNA offer a nonviral way to instruct cells—primarily liver cells—to temporarily make the missing enzyme. In GALT-deficient mice, repeated dosing restored liver GALT activity, reduced Gal-1-P in liver, red blood cells, brain, and ovaries, lowered plasma galactose, and improved survival during neonatal galactose exposure. GALT mRNA therapy in mice A related zebrafish proof-of-concept study found that human GALT mRNA packaged in lipid nanoparticles could restore GALT protein and enzyme activity during early development. GALT mRNA therapy in zebrafish A 2026 pilot study further reported improved motor-related outcomes in a GALT-deficient mouse model after experimental GALT mRNA treatment, extending the work beyond biochemical markers. GALT mRNA and motor phenotypes

Metabolite-lowering small molecules. Govorestat (AT-007) inhibits aldose reductase, the enzyme that converts galactose into galactitol. It does not repair GALT and therefore is not a cure, but it was the most clinically advanced disease-modifying approach. In the randomized ACTION-Galactosemia Kids study, 47 children aged 2–17 received govorestat or placebo for up to 18 months; the published report described sustained reductions in plasma galactitol and favorable results on several behavioral, adaptive-function, cognition, tremor, and fine-motor measures, while speech and gross-motor outcomes did not differ from placebo. ACTION-Galactosemia Kids results However, the FDA issued a Complete Response Letter in November 2024, concluding that the trial did not provide convincing evidence of effectiveness on prespecified primary endpoints and that galactitol had not been established as a reliable surrogate for clinical benefit. FDA Complete Response Letter for govorestat

Repairing residual enzyme activity or bypassing the block. For people with missense variants—mutations that produce an unstable but partly formed GALT protein—researchers are testing pharmacological chaperones, small molecules intended to stabilize the mutant enzyme. A 2025 laboratory study identified repurposed candidates that increased activity of purified mutant GALT and lowered Gal-1-P in patient fibroblasts, but the work remains preliminary and has not established safety or effectiveness in people. Pharmacochaperones for mutant GALT Separately, a 2024 fruit-fly study showed that restoring galactose metabolism through an alternative route, without restoring GALT itself, improved survival and adult motor performance, supporting metabolic bypass as an early-stage concept. Alternative galactose-metabolism rescue in flies

Clinical Trials and Experimental Approaches

The main completed interventional program has been govorestat. The pediatric ACTION-Galactosemia Kids trial, listed as NCT04902781 and sponsored by Applied Therapeutics, was a randomized, placebo-controlled Phase 3 study that completed in 2023. NCT04902781 Its published findings were encouraging for galactitol lowering and selected functional measures, but the FDA’s November 2024 decision required at least one new adequate and well-controlled clinical trial demonstrating benefit on clinically meaningful endpoints before approval could be reconsidered. FDA Complete Response Letter for govorestat

Earlier Phase 1/2 development of AT-007 included healthy adults and adults with classic galactosemia in NCT04117711. NCT04117711 By contrast, AAV gene therapy, mRNA replacement, pharmacological chaperones, and metabolic-bypass strategies remain preclinical; they should not be interpreted as available treatments. Reshaping the treatment landscape

Methodologies and Scientific Approaches

Researchers use complementary disease models because no single model fully reproduces all human complications. GALT-null rats reproduce important biochemical and clinical features and have been used to test AAV9 gene replacement; GALT-deficient mice enable repeated mRNA dosing and studies of neonatal survival, fertility, tissue metabolites, and motor behavior; zebrafish permit rapid early-development experiments; and fruit flies enable genetic and metabolic pathway screens. GALT-null rat model GALT mRNA therapy in mice GALT mRNA therapy in zebrafish Alternative galactose-metabolism rescue in flies

Key measurements include GALT enzyme activity, galactose, galactitol, and Gal-1-P in blood and tissues, alongside cataracts, survival, fertility, brain-related behavior, motor tests, cognition, speech, and daily functioning. A major methodological issue is that red-blood-cell Gal-1-P, although widely used clinically, may not reflect Gal-1-P concentrations in the brain, liver, or other affected organs. GALT-null rat model

Leading Institutions and Funding

Major academic contributors include Emory University School of Medicine, where the GALT-null rat and AAV9 replacement studies were developed; the University of Utah, which has led mRNA, mouse-model, and protein-stabilization research; and Maastricht University Medical Center and its collaborators, which have advanced zebrafish mRNA work, clinical-outcome research, and studies of neurologic and ovarian complications. AAV9 GALT gene replacement in rats GALT mRNA therapy in mice GALT mRNA therapy in zebrafish Pharmacochaperones for mutant GALT

Applied Therapeutics has been the principal biotechnology sponsor of the govorestat clinical program. NCT04902781 The Galactosemia Foundation is an important patient-led funder: it reports more than $931,595 awarded for galactosemia research to date, including 2021 awards of $50,000 for improved gene therapy in a rat model and $48,457 for “Marching towards a cure for CG”; its typical grants range from $10,000 to $50,000. Galactosemia Foundation funded research

Strengths, Limitations, and Challenges

The strongest evidence for a potential cure is biological: both AAV gene replacement and lipid-nanoparticle mRNA can restore GALT activity and reduce disease-related metabolites in multiple animal models. AAV9 GALT gene replacement in rats GALT mRNA therapy in mice mRNA has the advantage of avoiding permanent DNA insertion and allowing dose adjustment, but it will likely require repeat administration; AAV may provide more durable expression, but immune responses, redosing limitations, uneven delivery to brain and ovaries, and long-term safety must be resolved. Reshaping the treatment landscape

The govorestat experience also shows why lowering a biomarker is not enough. The FDA found that plasma galactitol reductions were modest, that associations between galactitol and clinical outcomes were weak or inconsistent in its review, and that the pivotal trial had efficacy-endpoint data-quality issues. FDA Complete Response Letter for govorestat More broadly, researchers still do not know how much GALT activity must be restored, how early treatment must begin to prevent irreversible neurologic or ovarian injury, or which combination of metabolic and functional measures best predicts long-term benefit. Reshaping the treatment landscape

Outlook and Future Directions

As of August 8, 2026, classic galactosemia is not close to an available one-time cure, but the research path is clearer than it was at the start of this decade. The most important milestones to watch are a human investigational-new-drug entry for GALT mRNA or gene replacement; durable correction of brain and ovarian disease in animal studies; validated biomarkers that track patient-relevant outcomes; and a rigorously designed new govorestat or other metabolite-targeting trial with clinically meaningful endpoints. Until then, prompt newborn screening, lifelong dietary management, and proactive support for developmental, neurologic, endocrine, and reproductive complications remain essential. Classic Galactosemia and Clinical Variant Galactosemia FDA Complete Response Letter for govorestat

References

Don't see your disease? Request a report